Abstract
Preclinical studies have shown that aprepitant, an antiemetic used to prevent chemotherapy-induced nausea and vomiting, slows mammary tumor growth and progression. Here, we evaluated the association between aprepitant and survival in a large cohort of women with early breast cancer.
Using linked nationwide registry data, we identified 13 811 women diagnosed with early breast cancer between 2008 and 2020 in Norway, who received chemotherapy and antiemetics. Women were followed for metastasis and death from 1 year after diagnosis until the end of 2021. To evaluate the association between aprepitant use and distant disease-free survival (DDFS) and breast cancer-specific survival (BCSS), we used Cox regression models, controlling for tumor and patient characteristics, chemotherapy regimens, and use of other antiemetics.
During chemotherapy, 7047 (51%) women were supplied with aprepitant. Overall, aprepitant use was associated with better DDFS (HRDDFS = 0.89; 95% CI = 0.79 to 1.00) and BCSS (HRBCSS = 0.83; 95% CI = 0.71 to 0.97). The survival advantage was specific to women with non-luminal breast cancer (HRDDFS = 0.69; 95% CI = 0.56 to 0.83; HRBCSS = 0.64; 95% CI = 0.51 to 0.81) and was strongest in women with triple negative breast cancer (TNBC) (HRDDFS = 0.66; 95% CI = 0.53 to 0.83; HRBCSS = 0.61; 95% CI = 0.47 to 0.80). In women with non-luminal breast cancer, longer durations of aprepitant use were associated with increasingly favorable survival outcomes (DDFS: Ptrend = .002; BCSS: Ptrend = .016). Supply of other antiemetics of different drug classes was not associated with survival.
Aprepitant use during chemotherapy treatment was associated with better prognosis for women with non-luminal early breast cancer, in particular TNBC. Long-term clinical trials are required to confirm these findings.
Article Contents
Similar articles
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Weibel S, Rücker G, Eberhart LH, Pace NL, Hartl HM, Jordan OL, Mayer D, Riemer M, Schaefer MS, Raj D, Backhaus I, Helf A, Schlesinger T, Kienbaum P, Kranke P.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2.PMID: 33075160 Free PMC article.
-
Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a network meta-analysis.Piechotta V, Adams A, Haque M, Scheckel B, Kreuzberger N, Monsef I, Jordan K, Kuhr K, Skoetz N.Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD012775. doi: 10.1002/14651858.CD012775.pub2.PMID: 34784425 Free PMC article.
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.PMID: 16959170
-
Platinum-containing regimens for metastatic breast cancer.Egger SJ, Willson ML, Morgan J, Walker HS, Carrick S, Ghersi D, Wilcken N.Cochrane Database Syst Rev. 2017 Jun 23;6(6):CD003374. doi: 10.1002/14651858.CD003374.pub4.PMID: 28643430 Free PMC article.
-
Platinum-based chemotherapy for early triple-negative breast cancer.Mason SR, Willson ML, Egger SJ, Beith J, Dear RF, Goodwin A.Cochrane Database Syst Rev. 2023 Sep 8;9(9):CD014805. doi: 10.1002/14651858.CD014805.pub2.PMID: 37681577 Free PMC article.
Plaats een reactie ...
Reageer op "Aprepitant, een antibraak middel bij chemotherapie, blijkt betere ziektevrije overleving op afstand en borstkankerspecifieke overleving te geven bij borstkankerpatienten met borstkanker in vroeg stadium"